Sorin Group Cardiac Rhythm Management (CRM) has reported the first implant in a clinical trial of its Paradym 8770 sonR cardiac resynchronization therapy defibrillator (CRT-D).
The company said its system contains sonR, designed to adjust CRT delivery based on hemodynamic response as opposed to conventional CRT-D devices. Paradym sonR is the first device delivering continuous management of resynchronization therapy during patients’ everyday life, according to the Paris-based Sorin.
“Whereas conventional devices look at the heart as a ‘clock,’ new Paradym sonR looks at the heart as a ‘pump,’ measuring vibrations generated by heart contraction,” said Fred Hrkac, president of Sorin CRM business unit.
A multi-center clinical trial including 150 patients is currently being conducted across Europe. The company said its first sonR systems, the Paradym sonR CRT-D, including the sonR Fix atrial lead, were implanted by Angelo Auricchio, MD, from Cardiocentro Ticino in Lugano, Switzerland; Peter Paul Delnoy, MD from Isala Clinics in Zwolle, Netherlands; and Neil Sulke, MD from Eastbourne General Hospital in the East Sussex, England.